The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Share News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 310.00
Bid: 307.00
Ask: 312.00
Change: 0.00 (0.00%)
Spread: 5.00 (1.629%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 310.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Origin Enterprises loss slims; Amryt issues guidance

Thu, 04th Mar 2021 12:46

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Origin Enterprises PLC - Dublin-based agri-services provider - Revenue for six months to end of January falls to EUR572.4 million from EUR604.9 million, though pretax loss slims to EUR2.5 million from EUR7.2 million. "Operating profit of EUR1.2 million in the period compared favourably to a loss of EUR2.8 million in H1 2020. This was largely as a result of a more normalised cropping profile across the group, set against last year's highly unseasonal and prolonged weather conditions which materially impacted business performance in H1 2020," says Chief Executive Sean Coyle. Says first half performance sets "positive foundation" for full-year, though uncertainties remain heading into the seasonally more important second half. Says well-placed to deliver "good" growth in earnings for full-year.

----------

Amryt Pharma PLC - London-based biopharmaceutical company - Reports 19% growth in 2020 revenue to USD182.6 million, though pretax loss widens to USD105.9 million from USD63.5 million. Selling, general and administrative expenses more than double to USD76.7 million from USD35.5 million. "Our business continues to perform and grow strongly. In particular, our revenue growth exceeded expectations and the fact that we turned Ebitda profitable has translated into a significant increase in our cash balances. Given the strong performance of our business in 2020, we are now issuing revenue guidance for FY 2021 of [between USD200 million and USD205 million] which demonstrates our confidence in Amryt's prospects," says Chief Executive Joe Wiley.

----------

Hutchison China Meditech Ltd - China-based biopharmaceutical company - Total revenue for 2020 USD228.0 million, up from USD204.9 million the year before. Net loss widens to USD115.5 million from USD103.7 million. Guides to Oncology/Immunology consolidated revenue of USD110 million toUSD130 million, versus USD30.2 million in 2020. Adds it intends to seek shareholder approval to change it name to Hutchmed China Ltd to its forthcoming annual general meeting. "Over the next three years, we will continue to grow our R&D and commercial organizations globally to support the anticipated launch of our oncology drugs in China, the US and Europe," says Chair Simon To.

----------

Syncona Ltd - investor in life science companies - Notes portfolio company, Autolus Therapeutics PLC, reports net loss of USD142.1 million for 2020, wider than USD123.8 million in 2019. "Autolus' primary focus is on delivering the potential pivotal Auto1 program and the company starts 2021 in a position of financial strength, having raised a total of USD131 million in gross proceeds this quarter, giving us a cash runway into the first half of 2023," says Christian Itin, chair and chief executive of Autolus.

----------

Cairn Homes PLC - Irish homebuilding company - Revenue for 2020 slumps to EUR261.9 million from EUR435.3 million in 2019, while pretax profit drops over 100% to EUR14.8 million from EUR58.6 million. Says current closed and forward order book of new homes underpins growth for 2021 with an underlying margin "comfortably higher" than reported margin in 2020. 2020 operating margin weakened to 9.3% from 15.6%. "Our construction sites have been closed since the start of the year and assuming they fully reopen on 6 April 2021, Cairn's construction activities will be limited to just over 8 months in the current year. This will have an impact on the number of new homes which we will be able to build and sell in 2021," company says.

----------

Pacific Horizon Investment Trust PLC - invests in Asia-Pacific region excluding Japan and Indian sub-continent - Reports net asset value per share of 699.01 pence at end of January, up 45% from 481.92p at July-end. NAV per share total return 45% while share price total return was 53% as the premium increased to 10% from 4.6%. Over the same period the MSCI All Country Asia ex Japan Index's total return was 21% in sterling terms. "Our holdings outperformed in most regions. At the index level, Materials was the best performing sector, up 70.0%, followed by Consumer Discretionary up 49.5% and Communications Services up 48.7%. The worst were Information Technology, up 34.6%, Industrials up 22.6% and Energy up 5.7%," firm says.

----------

Mid Wynd International Investment Trust PLC - looks to invest in high quality companies, with proven profitability and high levels of cash generation - Net asset value per share at December 31 698.66p, up 14% from 612.61p at June 30 and 581.10p at end of 2019. For six months to end of December, company's share price rose 18% on a total return basis with dividends assumed to be re-investment, while NAV per share rose 15% on total return basis. This compares to a total return from the MSCI All Country World Index (GBP) of 12%. "Although we have outperformed our comparator index, which is of course pleasing, this outperformance would have been greater had we held Tesla and more Apple shares in line with the index," firm notes.

----------

Hansard Global PLC - specialist long-term savings provider - Says new business levels GBP76.3 million for half-year to December 31 on a present value of new business premiums basis, down 4.7% on a year ago. Pretax profit up 12% to GBP2.9 million from GBP2.6 million year-on-year due to lower new business acquisition costs. Declares stable interim dividend of 1.8p per share.

----------

Online Blockchain PLC - holds around 18% stake in investor website operator ADVFN PLC and incubates developers of blockchains and cryptocurrencies - Revenue for six months to December 31 GBP56,000, increasing 27% from GBP44,000 a year ago, while pretax loss slims to GBP76,000 from GBP144,000. Says it is excited for prospects for blockchain, "irrespective" of the value of bitcoin in 2021. Notes that ADVFN PLC, its largest asset, reports revenue of GBP4.2 million over the same period, up from GBPP3.7 million a year ago.

----------

Crystal Amber Fund Ltd - activist fund investing in small and mid-cap UK equities - Net asset value per share grew 22% over the six months to December 31 to 129 pence, versus a 24% increase in Numis Small Cap Index. "The period under review saw ongoing uncertainty from the Covid-19 pandemic, as well as final Brexit negotiations. The latter adversely affected the appetite of global investors for UK stocks, specifically small and medium sized companies, as well as the appetite of corporate acquirers for attractively priced targets," firm says, adding that this has left many UK companies undervalued by international standards and if the UK's rapid vaccination programme does translate into earlier economic recovery, there should be a re-rating.

----------

ThinkSmart Ltd - specialist digital payments business - Total revenue for six months to December 31 GBP2.4 million from GBP3.3 million, though pretax profit jumps to GBP53.7 million from GBP16.0 million after recording GBP52.9 million gain on financial instruments versus GBP16.6 million a year ago. "While our strategic efforts are focused on further value creation for shareholders via our holding in Clearpay, the managed wind down of our legacy operations continues to generate positive cash flow as we control costs while rightsizing the operations to lower volumes. This leaves our balance sheet robust. There is inherent, tangible value within our proprietary payments technology and we are continuing to consider how best to optimise the value of this asset," Executive Chair Ned Montarello says.

----------

Manx Financial Group PLC - Isle of Man-based financial services firm - Net interest income for 2020 GBP15.5 million, down from GBP17.9 million in 2019. Net trading income edges down 3.7% to GBP15.4 million from GBP16.0 million. Pretax loss falls 33% to GBP2.0 million from GBP3.0 million, with impairments on loans and advances to customers rising to GBP4.0 million from GBP1.9 million. "The Isle of Man has successfully bounced back from lockdowns, as shown by the less than expected uptake in the government support schemes, our positive lending figures and the encouraging recent government budget. As such, I expect a continued improvement in the economy on Island which will, in turn, create a positive environment for our lending and wealth management businesses to operate within," company says.

----------

Franchise Brands PLC - Macclesfield-based multi-brand franchise business - Reports revenue of GBP49.3 million for 2020, up 12% on 2019's GBP44.0 million. Pretax profit rises 12% to GBP3.7 million from GBP3.3 million. "Resilient performance following strong growth in Q1, early and decisive action taken during the Spring lockdown to reduce costs, and a strong recovery across the majority of businesses during the second half of the year," company says. Proposes final dividend for 2020 of 0.8p per share, up from 0.65p in 2019, to give total payout of 1.1p, up 16%. Says trading has started strongly in 2021, with resilient sales in the B2B division and robust recruitment in the B2C division.

----------

Airea PLC - West Yorkshire-based floor coverings manufacturer - Revenue for 2020 falls 24% to GBP14.6 million from GBP19.2 million in 2019, while pretax profit dives to GBP500,000 from GBP2.0 million. Says after strong start in first quarter, the pandemic hit the group's ability to trade. "Whilst the group remained open for business throughout the year management had to reassess its strategic priorities and made the decision to prioritise cash and working capital to provide the best defence against uncertainty," company says.

----------

MediaZest PLC - London-based audio visual services firm - Reports revenue of GBP3.1 million for eighteen months to September 30 versus GBP3.3 million in the twelve months to March 31, 2019. Swings to pretax loss of GBP478,000 from GBP6,000 profit. Says results for eighteen month period hit by pandemic, with a significant reduction in revenue particularly during the first UK lockdown. "At this time, it remains difficult to fully assess the extent to which the Pandemic will affect the group's forthcoming trading and financial performance as the situation continues to evolve. The second national lockdown in November 2020 and closure of many retail businesses had an impact, however new project pitches have increased in number since the start of 2021, despite the third national lockdown coming into effect," Mediazest says. Firm working on the assumption that the disruption caused by the pandemic will have an impact "deep" into 2021.

----------

By Lucy Heming; lucyheming@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
29 Aug 2023 09:30

IN BRIEF: China grants Hutchmed's savolitinib breakthrough therapy tag

Hutchmed (China) Ltd - Hong Kong-based developer of treatments for cancer and immunological diseases - Wins 'breakthrough therapy designation' in China for its gastric cancer treatment, savolitinib. The BTD is granted by the National Medical Products Administration. It is for the treatment of locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma patients with mesenchymal epithelial transition factor amplification who have failed at least two lines of standard therapies. Hutchmed notes that MET-driven gastric cancer has a poor prognosis, and China grants a BTD to new drugs that treat life-threatening diseases for which there are no effective treatment options.

Read more
21 Aug 2023 08:46

Hutchmed China hails trial on sovleplenib meeting primary endpoint

(Alliance News) - Hutchmed (China) Ltd on Monday said a phase 3 trial evaluating the investigational use of sovleplenib met its primary endpoint.

Read more
21 Aug 2023 08:24

Hutchmed meets all endpoints in platelet disorder treatment trial

(Sharecast News) - Hutchmed China reported a breakthrough from its recent phase three trial in sovleplenib on Monday, reporting that it met its primary endpoint and all secondary endpoints for treating adult patients with primary immune thrombocytopenia - a platelet disorder - (ITP) in China.

Read more
31 Jul 2023 12:47

Hutchmed swings to profit after "sharpening goals and priorities"

(Alliance News) - Hutchmed (China) Ltd on Monday reported sharp first-half revenue growth, as a strategy change to boost its fortunes outside of China saw early fruit.

Read more
24 Jul 2023 15:46

UK earnings, trading statements calendar - next 7 days

Tuesday 25 July 
City of London Investment Group PLCTrading Statement
Compass Group PLCTrading Statement
Croda International PLCHalf Year Results
Games Workshop Group PLCFull Year Results
Greencore Group PLCTrading Statement
Hummingbird Resources PLCTrading Statement
MITIE Group PLCTrading Statement
Paragon Banking Group PLCTrading Statement
Reach PLCHalf Year Results
Smart Metering Systems PLCTrading Statement
Tristel PLCTrading Statement
Tyman PLCHalf Year Results
Unilever PLCHalf Year Results
Unite Group PLCHalf Year Results
Wednesday 26 July 
Aptitude Software Group PLCHalf Year Results
Breedon Group PLCHalf Year Results
Conduit Holdings LtdHalf Year Results
Ecora Resources PLCTrading Statement
Fresnillo PLCTrading Statement
FRP Advisory Group PLCFull Year Results
Gresham Technologies PLCHalf Year Results
Lloyds Banking Group PLCHalf Year Results
Marston's PLCTrading Statement
Nichols PLCHalf Year Results
Primary Health Properties PLCHalf Year Results
Rathbones Group PLCHalf Year Results
Revolution Bars Group PLCTrading Statement
Rio Tinto PLCHalf Year Results
Science Group PLCHalf Year Results
Van Elle Holdings PLCFull Year Results
Thursday 27 July 
Allianz Technology Trust PLCHalf Year Results
Antofagasta PLCHalf Year Results
Capital & Regional PLCHalf Year Results
Card Factory PLCTrading Statement
Checkit PLCTrading Statement
Drax Group PLCHalf Year Results
Deliveroo PLCHalf Year Results
Derwent London PLCHalf Year Results
Entain PLCHalf Year Results
Greencoat UK Wind PLCHalf Year Results
Global Connectivity PLCHalf Year Results
Hostelworld Group PLCHalf Year Results
HydrogenOne Capital Growth PLCTrading Statement
Lancashire Holdings LtdHalf Year Results
Mitchells & Butlers PLCTrading Statement
OSB Group PLCHalf Year Results
Persimmon PLCHalf Year Results
Petrofac LtdHalf Year Results
Redcentric PLCFull Year Results
S&U PLCTrading Statement
Savills PLCHalf Year Results
Secure Trust Bank PLCHalf Year Results
Spirax-Sarco Engineering PLCHalf Year Results
Videndum PLCHalf Year Results
Wheaton Precious Metals CorpHalf Year Results
Friday 28 July 
AIB Group PLCHalf Year Results
GCP Infrastructure Investments LtdTrading Statement
International Consolidated Airlines Group SAHalf Year Results
Intertek Group PLCHalf Year Results
Jardine Matheson Holdings LtdHalf Year Results
NatWest Group PLCHalf Year Results
PayPoint PLCFull Year Results
PayPoint PLCTrading Statement
Standard Chartered PLCHalf Year Results
YouGov PLCTrading Statement
Monday 31 July 
Hutchmed (China) LtdHalf Year Results
Pearson PLCHalf Year Results
Pod Point Group Holdings PLCHalf Year Results
Quartix Technologies PLCHalf Year Results
Spectris PLCHalf Year Results
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
20 Jul 2023 14:14

IN BRIEF: Hutchmed progresses fruquintinib designation and testing

Hutchmed (China) Ltd - Hong Kong-based developer of treatments for cancer and immunological diseases - Granted breakthrough therapy designation, by the Center for Drug Evaluation of China's National Medical Products Administration, for oral inhibitor fruquintinib combined with PD-1 antibody sintilimab. BTD is for treatment of patients with previously treated advanced endometrial cancer.

Read more
10 Jul 2023 12:58

Hutchmed launches new phase one study in China

(Sharecast News) - Biopharmaceutical company Hutchmed China announced the launch of a phase one study in China for HMPL-415 on Monday - an investigational selective allosteric inhibitor that targeted Src homology-2 domain-containing protein tyrosine phosphatase-2 (SHP2).

Read more
10 Jul 2023 08:53

IN BRIEF: Hutchmed starts study for tumour treatment in China

Hutchmed (China) Ltd - Hong Kong-based cancer and immunological diseases' treatment developer - Starts phase one study in China of its SHP2 inhibitor HMPL-415 for the treatment of advanced malignant solid tumours. First patient received their first dose on Thursday last week. Hutchmed expects up to 80 patients to take part in the study. SHP2 is a non-receptor protein tyrosine phosphatase which controls cell growth and cell migration.

Read more
16 Jun 2023 08:51

Hutchmed, Takeda Fresco-2 study published in The Lancet

(Alliance News) - Hutchmed (China) Ltd on Friday said phase three results for its Fresco-2 study evaluating fruquintinib in patients with previously treated metastatic colorectal cancer, conducted alongside Takeda Pharmaceutical Co Ltd, were published in peer-reviewed journal, The Lancet.

Read more
16 Jun 2023 08:44

Hutchmed China's colorectal cancer study to be published

(Sharecast News) - Hutchmed China, alongside its partner Takeda, announced the publication of the phase three 'FRESCO-2' study results evaluating the use of fruquintinib in patients with previously-treated metastatic colorectal cancer (CRC) on Friday, in the Lancet medical journal.

Read more
15 Jun 2023 16:51

IN BRIEF: Hutchmed and Takeda get Europe marketing backing for drug

Hutchmed (China) Ltd - Hong Kong-based cancer and immunological diseases treatment developer - Says marketing authorisation application for fruquintinib, made alongside Tokyo-based Takeda Pharmaceutical Co Ltd, has been validated and caccepted by the European Medicines Agency. Fruquintinib is an inhibitor of vascular endothelial growth factor receptors used to treat cancers.

Read more
26 May 2023 13:13

US FDA gives priority to Hutchmed's colorectal cancer treatment

(Sharecast News) - Hutchmed China, in collaboration with Takeda, announced on Friday that the US Food and Drug Administration (FDA) has granted priority review for the New Drug Application (NDA) of fruquintinib.

Read more
26 May 2023 08:56

Hutchmed China celebrates FDA review, teases new data at ASCO meeting

(Alliance News) - Hutchmed China Ltd on Friday celebrated a priority review granted by the US FDA for its cancer drug fruquintinib, and promised to present new data for this and two other therapies at the American Society of Clinical Oncology next month.

Read more
5 May 2023 15:57

UK shareholder meetings calendar - next 7 days

Monday 8 May 
no events scheduled 
Tuesday 9 May 
Caledonia Mining Corp PLCAGM
Direct Line Insurance Group PLCAGM
Foxtons Group PLCAGM
Hostelworld Group PLCAGM
IWG PLCAGM
Just Group PLCAGM
Midwich Group PLCAGM
Osirium Technologies PLCAGM
Windward LtdAGM
Wednesday 10 May 
abrdn PLCAGM
Antofagasta PLCAGM
Cenkos Securities PLCAGM
Ecora Resources PLCAGM
H&T Group PLCAGM
Harbour Energy PLCAGM
Jupiter Fund Management PLCAGM
Literacy Capital PLCAGM
Luceco PLCAGM
Marshalls PLCAGM
National Express Group PLCAGM
Renewables Infrastructure Group LtdAGM
Rentokil Initial PLCAGM
Seplat Energy PLCAGM
Spirax-Sarco Engineering PLCAGM
TClarke PLCAGM
Thursday 11 May 
88 Energy LtdAGM
Cairn Homes PLCAGM
Capita PLCAGM
Clarkson PLCAGM
Costain Group PLCAGM
Eleco PLCAGM
Eurocell PLCAGM
FBD Holdings PLCAGM
Genedrive PLCGM re Equity Prepayment Facility
Genel Energy PLCAGM
Gresham House PLCAGM
Gym Group PLCAGM
Hiscox LtdAGM
Irish Continental Group PLCAGM
John Wood Group PLCAGM
MyHealthChecked PLCAGM
OSB Group PLCAGM
Poolbeg Pharma PLCAGM
Rolls-Royce Holdings PLCAGM
Serinus Energy PLCAGM
Uniphar PLCAGM
Videndum PLCAGM
WAG Payment Solutions PLCAGM
Friday 12 May 
Balfour Beatty PLCAGM
Derwent London PLCAGM
Goodbody Health LtdAGM
GreenRoc Mining PLCAGM
Hutchmed (China) LtdAGM
Itim Group PLCAGM
Itsarm PLCGM re delisting from AIM
Wheaton Precious Metals CorpAGM
  
Copyright 2023 Alliance News Ltd. All Rights Reserved. 

Read more
18 Apr 2023 12:30

Hutchmed's gastric cancer treatment accepted for review in China

(Sharecast News) - Hutchmed China announced on Tuesday that its new drug application (NDA) for fruquintinib, in combination with paclitaxel has been accepted for review by the National Medical Products Administration (NMPA) in China.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.